Loading...
Market
Story
Pfizer's RSV Vaccine Abrysvo Shows Positive Results in Study
Aug 12, 2024, 10:48 AM
Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has shown positive results in a late-stage study involving immunocompromised adults. The study demonstrated that Abrysvo generated a strong immune response across four groups of adults. This development marks a significant step for Pfizer as it seeks to expand its vaccine offerings and address the needs of vulnerable populations.
View original story
Similar markets
Pfizer • 25%
GlaxoSmithKline • 25%
Moderna • 25%
Other • 25%
Pfizer leads • 25%
GSK leads • 25%
Moderna leads • 25%
Other leads • 25%
Pfizer's ABRYSVO® • 25%
GSK's RSV vaccine • 25%
Moderna's RSV vaccine • 25%
Other • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Sanofi • 25%
Other • 25%
Yes • 50%
No • 50%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Pfizer • 25%
Merck • 25%
Both equally • 25%
Neither • 25%
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%